Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 271-280 of 460 for breast cancer

Edit search filters
  1. A Study of PY314 in Subjects With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

    Rochester, MN

  3. A Study to Evaluate S-Adenosyl-L-Methionine for the Treatment of Hot Flashes

    Rochester, MN

  4. Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.

    Jacksonville, FL

  5. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

    Scottsdale/Phoenix, AZ

  6. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  7. A Study To Evaluate The Safety And Efficacy Of A2B395, An Allogeneic Logic-gated CAR T, In Participants With Solid Tumors That Express EGFR And Have Lost HLA-A*02 Expression

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

  10. A Study to Evaluate the Effectiveness and Safety of Rivaroxaban as Prophylaxis Treatment for Venous Thromboembolism (VTE) in Ambulatory Cancer Patients

    Rochester, MN

.

Mayo Clinic Footer